Vident Advisory’s Novo Nordisk NVO Stock Holding History

Vident Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.36M	Sell	36,912 -4,751	-11%	-$225K	0.01%	750
2025 Q4	$2.12M	Sell	41,663 -4,960	-11%	-$254K	0.02%	561
2025 Q3	$2.59M	Sell	46,623 -3,137	-6%	-$184K	0.02%	486
2025 Q2	$3.43M	Sell	49,760 -1,386	-3%	-$94.3K	0.04%	362
2025 Q1	$3.55M	Buy	51,146 +9,685	+23%	+$800K	0.05%	310
2024 Q4	$3.57M	Sell	41,461 -1,555	-4%	-$168K	0.06%	282
2024 Q3	$5.12M	Buy	43,016 +7,049	+20%	+$940K	0.13%	153
2024 Q2	$5.13M	Buy	35,967 +4,445	+14%	+$589K	0.14%	140
2024 Q1	$4.05M	Buy	31,522 +1,258	+4%	+$150K	0.08%	244
2023 Q4	$3.13M	Sell	30,264 -447	-1%	-$44.2K	0.08%	275
2023 Q3	$2.79M	Buy	+30,711	New	+$2.71M	0.09%	244

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Vident Advisory's NVO Position: Q1 2026 in Review

Vident Advisory reduced its Novo Nordisk (NVO) stake by 11% in Q1 2026, selling an estimated $225K and leaving 36,912 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #750.

Vident Advisory first reported a position in NVO in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.13M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Vident Advisory held 36,912 shares of Novo Nordisk worth $1.36M as of Q1 2026.
Vident Advisory sold 4,751 Novo Nordisk shares in Q1 2026, an estimated $225K.
Novo Nordisk made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #750 holding.
Vident Advisory first reported a position in Novo Nordisk in Q3 2023 and has held it in 11 quarters since.
Vident Advisory's Novo Nordisk position peaked at $5.13M in Q2 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.